General contact

Novartis Pharmaceuticals UK Limited
UK Head Office
Frimley Business Park Frimley
Camberley Surrey GU16 7SR

+44 1276 692255
+44 1276 692508
Monday - Friday,
8:30 - 17:30


Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel

+41 61 324 79 44


Novartis UK Press Office
Press Office enquiries only

+44 1276 698691

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

pane 4 content

Novartis UK homepage banner - Here and Now

Join our team!

We're looking for individuals who aspire to deliver outstanding results for both our business and for patients ... is that you? Learn more here. ..........................................................................

Listen to Vicky's story. She's recently joined our team of Key Account Managers and shares her initial experiences and thoughts on joining Novartis.


Novartis signs an exclusive agreement for the promotion of Ultibro® Breezhaler® and Seebri® Breezhaler® in the United Kingdom

4 September 2014 Novartis Pharmaceuticals UK Ltd signed an exclusive promotional agreement with Pfizer Ltd for Ultibro® Breezhaler® (indacaterol / glycopyrronium bromide) and Seebri® Breezhaler® (glycopyrronium bromide) in the United Kingdom.

Novartis' New Heart Failure Medicine LCZ696 Cuts Cardiovascular Deaths by 20% vs. ACE-Inhibitor in Landmark PARADIGM-HF

31 August 2014 Novartis has revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever done.

UK Here & Now campaign launched today

24-June-2014 The campaign aims to raise awareness of Advanced breast cancer and the realities of living with the disease, in order to improve the level of care and support available.

New ‘Wheals of Despair’ report reveals that CSU – a distressing and disfiguring form of chronic hives affecting up-to half a million Brits[i] – needs urgent NHS reprioritisation

13-June-2014 A new report published today sets out six key challenges faced by those living with chronic spontaneous urticaria (CSU) and those responsible for its diagnosis and management.

Top Links